Basic and clinical aspects are discussed by expert contributors in this book devoted to stimulating further studies and developing new therapies for pulmonary fibrosis. Current laboratory and basic findings are reviewed in the book's first 19 chapters, while clinical aspects are addressed in the remaining 16 chapters. These aspects include laboratory and bronchalveolar findings, diagnosis, treatment and prognosis of idiopathic pulmonary fibrosis, collagen disease lungs, sarcoidosis, pneumoconiosis, hypersensitive pneumonia, drug-induced pneumonia, ARDS, radiation pneumonia, BOOP, viral pneumonia, and other diseases causing pulmonary fibrosis. The roles of various cytokines, viral infection, and lung injuries in the development and pathogenesis of pulmonary fibrosis are discussed. The definition, classification, and lung functions of pulmonary fibrosis are included as well.

This clinically focused pocket guide offers a concise yet complete overview of idiopathic pulmonary fibrosis, covering the most recent information on aspects such as pathophysiology, management, treatment, and clinical trials. The text is easily accessible and offers pulmonologists and other health care professionals with an excellent quick reference tool. Full color images and figures enhance and summarize key aspects of the text. Idiopathic pulmonary fibrosis is a condition that affects the alveoli and leads to serious lung damage, and the idiopathic nature of this disease means that the origin or cause is unknown. This disease is relatively rare, affecting 3 in 10,000 people, but it is becoming more common. Physicians should be aware of the early stages and symptoms of this disease so management strategies can be implemented quickly, and the best treatment can be administered.

This international and authoritative work, which brings together current knowledge in the field of cystic fibrosis, has become established in previous editions as a leading reference in the field. The third edition continues to provide everything that the clinician or allied health professional treating patients with cystic fibrosis will need in a single manageable volume. Thoroughly revised and updated throughout, it reflects the significant advances that have been made in the field since the second edition published in 2000. Cystic Fibrosis evaluates in detail the basic science that underlies the disease and its progression, putting it into a clinical context. Diagnostic and clinical aspects are covered in depth, as are monitoring the condition and the importance of multi-disciplinary care, reflected in the sections into which the new edition has been sub-divided to improve accessibility. Future developments, including novel therapies, are covered in a concluding section. The clinical areas have been much expanded, with the introduction of separate chapters covering sleep, lung mechanics and the work of breathing, upper airway disease, insulin deficiency and diabetes, bone disease, and sexual and reproductive issues. A new section on monitoring discusses the use of databases to improve patient care, and covers monitoring in different age groups, exercise testing and the outcomes of clinical trials in these areas. Separate chapters are devoted to paramedical issues, including nursing, physiotherapy, psychology, and palliative and spiritual care. Throughout, the emphasis is on providing an up-to-date and balanced review of both the clinical and basic sciences aspects of the subject, and to reflect the multi-disciplinary nature of the cystic fibrosis care team. Drawing on the expertise of a team of international specialists from a variety of backgrounds, the third edition of Cystic Fibrosiswill continue to find a broad readership among respiratory physicians, paediatricians, specialist nurses and other health professionals working with patients with cystic fibrosis.

Cystic Fibrosis has seen dramatic advances in treatment since the last edition, including targeted cystic fibrosis transmembrane conductance regulator (CFTR) protein modulators for most CFTR gene abnormalities. This new fifth edition is an update and expansion of the rapid clinical and scientific advances in improving prognosis, and the impact of COVID-19, all of which has transformed conventional models of care. It covers basic science, such as how detailed understanding of the biology of the CFTR gene and protein has led to novel and beneficial therapies, as well as all aspects of clinical management in high-, middle- and low-income settings and the voices of individuals with CF from across the world. It will be a useful reference for clinicians, including all levels of trainees, across the whole multidisciplinary team, scientists and students. Key Features • Follows an appealing organization of chapters, by developing fundamental knowledge of the reader before moving on to more complex or developing topics. • Presents a comprehensive, authoritative and up-to-date text, integrating fundamental science and clinical aspects of cystic fibrosis providing an attractive read for clinicians, trainee doctors and scientists. • Draws on global expertise and reflects best evidence-based practice from experts conducting cutting-edge clinical and basic science research from around the world.

Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide delivers a concise review of our current understanding of disease pathogenesis and provides current evidence in the medical literature regarding its diagnosis and management. Each chapter includes key points and a summary aiming to update clinicians about various issues concerning the diagnosis and management of IPF. In addition to outlining the current state of knowledge, each chapter also provides a summary of ongoing research and identifies the needs for future research in the field. Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide is an important new text that provides its readers with a better understanding of the pathobiology and natural history of IPF as it continues to evolve.

A discussion of the epidemiology, clinical features, and differential diagnoses of idiopathic pulmonary fibrosis (IPF). Key topics include the role of polymorphonuclear leukocytes in the pathogenesis of pulmonary fibrosis, and current treatment options, including medical therapy and lung transplantation.

Idiopathic pulmonary fibrosis (IPF) is a steadily progressive and ultimately fatal disease of unknown origin. Recent years have seen advances in our understanding of IPF and a number of guidelines have been published. But many questions remain unanswered, particularly surrounding probable versus definite IPF. This Monograph aims to discuss the latest achievements in IPF, and covers key diagnostic issues, staging of the disease, complications and comorbidities, treatment, unmet patient needs and perspectives for the future. This book will be of interest to all clinicians and researchers in this area.

This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions. It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.

This work contains updated and clinically relevant information about tuberculosis. It is aimed at providing a succinct overview of history and disease epidemiology, clinical presentation and the most recent scientific developments in the field of tuberculosis research, with an emphasis on diagnosis and treatment. It may serve as a practical resource for students, clinicians and researchers who work in the field of infectious diseases.

Clinically focused and designed to provide a to-the-point overview, Interstitial Lung Disease, by Drs. Talmadge King, Harold Collard, and Luca Richeldi, bring you up to date with increased understanding, new treatment protocols, and recent advances in the field. Written by contributing specialists who are global experts in their respective areas, this one-stop reference provides pulmonologists, intensivists, internal medicine physicians, and researchers with a dependable source of information on current treatment options and patient care.• Evidence for current treatment options for interstitial pneumonia, idiopathic pulmonary fibrosis, and smoking-related interstitial lung diseases. • Approach to diagnosis of interstitial lung diseases, such as sarcoidosis, hypersensitivity pneumonitis, and Churg-Strauss syndrome.• Genetic markers for inherited interstitial lung diseases such as dyskeratosis congenita, tuberous sclerosis/LAM, and hyper-IgE syndrome.